

PROPEL™ mometasone furoate sinus implants

Strengthen your sinus surgery arsenal with the PROPEL family of implants

The PROPEL family of steroid-releasing implants are designed for use post-ethmoid or frontal sinus surgeries, providing physicians a clinically demonstrated solution for their patients.¹⁻⁵



furoate implant

PROPEL™ Mini mometasone furoate implant



PROPEL™ Contour mometasone furoate implant

Packaging	Implant	Delivery system	Delivery system tip diameter	Implant nominal height	lmplant diameter	Sinus indication	CFNs
and device the second	PROPEL mometasone furoate implant	Straight	5.2 mm	23 mm	50.0 mm	Ethmoid sinus	70011
	PROPEL Mini mometasone furoate implant	Curved	4.0 mm	16 mm	42.5 mm	Ethmoid sinus and Frontal sinus opening	60011
(c) A-1	PROPEL Contour mometasone furoate implant	Flextip	2.8 mm	8 mm	15.5 mm	Frontal Sinus	50011-



PROPEL™ mometasone furoate implant




Step 1 Compress the implant circumferentially into a cylinder using all fingers

Step 3

Insert through funnel



Step 2 Allow implant to "flower" with 3 fingers to ensure no twisted or crossed struts; recrimp if cross struts occurs



Step 4 Carefully remove funnel while pinching implant inside delivery system

Do not expose PROPEL implants to fluid or gels prior to use (do not dip in saline)

PROPEL implants can be loaded twice, if needed

Load PROPEL sinus implants no more than 3 minutes before use to avoid reducing radial force



PROPEL™ Mini mometasone furoate implant



Step 1 Place implant inside crimping device



Step 2 Hover index finger over implant while slowly pulling "zip tie"




Depress plunger and shape

flexible tip to desired angle




PROPEL™ Contour mometasone furoate implant

Step 2 Grasp implant between fingers of both hands and gently compress implant



Step 1

Step 3 Insert compressed implant into the funnel



Step 4 Remove the funnel, and the delivery system is ready to be inserted with the tip facing superiorly



Step 3 Insert implant into delivery system with funnel facing superiorly



Medtronic

Medtronic Australasia Pty Ltd 2 Alma Road Macquarie Park NSW 2113 Australia Tel: +61 2 9857 9000 Fax: +61 2 9889 5167 Toll Free: 1800 668 670

©2024 Medtronic. All Rights Reserved. 12948727 | AU-ENT-2400017

The PROPEL sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection.

- 1. Forwith KD, Chandra RK, Yun PT, Miller SK, Jampel HD. ADVANCE: a multisite trial of bioabsorbable steroid-eluting sinus implants. Laryngoscope. 2011;121(11):2473-2480. doi:10.1002/lary.22228, Sponsored by Intersect ENT
- 2. Marple BF, Smith TL, Han JK, et al. Advance II: a prospective, randomized study assessing safety and efficacy of bioabsorbable steroid-releasing sinus implants. Otolaryngol Head Neck Surg. 2012;146(6):1004-1011. doi:10.1177/0194599811435968, Sponsored by Intersect ENT (now part of Medtronic)
- 3. Murr AH, Smith TL, Hwang PH, et al. Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent [published correction appears in Int Forum Allergy Rhinol. 2019 Aug; 9(8):945]. Int Forum Allergy Rhinol., Sponsored by Intersect ENT (now part of Medtronic)
- 4. Smith TL, Singh A, Luong A, et al. Randomized controlled trial of a bioabsorbable steroid-releasing implant in the frontal sinus opening [published correction appears in Laryngoscope, 2020 Mar; 130(3):8361, Laryngoscope, 2016; 126(12):2659-2664, doi:10.1002/lary.26140, Sponsored by Intersect ENT (now part of Medtronic)
- 5. https://clinicaltrials.gov/ for additional details on the EXCEED (NCT02228720) and PROGRESS (NCT02266810) clinical studies. Sponsored by Intersect ENT (now part of Medtronic)

This material does not replace the Instructions for Use. Please refer to the product insert or Instructions for Use for a complete list of indications, contraindications, warnings, precautions, and other important medical information. Always follow the Instructions for Use. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.com.au.

